Centro de presentaciones

Centro de presentaciones

Featured
LO MÁS NUEVO

Contenido recomendado

COVID-19 and its implications in heart failure
PRESENTACIÓN
COVID-19 and its implications in heart failure
Ver contenido
Can new-onset diabetes be prevented
PRESENTACIÓN
Can new-onset diabetes be prevented
Ver contenido
Practicalities of SGLT2 inhibition – pros vs cons
INFOGRAFÍA
Practicalities of SGLT2 inhibition – pros vs cons
Ver contenido
Updates on ESC heart failure guidelines
VIDEO
Updates on ESC heart failure guidelines
Ver contenido
Cardiologist Practical Guide to Prescribing
INFOGRAFÍA
Cardiologist Practical Guide to Prescribing
Ver contenido
Cardiovascular
LO MÁS NUEVO

Cardiovascular

Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
PRESENTACIÓN
Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
Ver contenido
What did the study tell us about the safety of medicines in heart failure?
PRESENTACIÓN
What did the study tell us about the safety of medicines in heart failure?
Ver contenido
Hiding in plain sight – how to detect heart failure in primary care
PRESENTACIÓN
Hiding in plain sight – how to detect heart failure in primary care
Ver contenido
Optimizing HF discharge care and follow-up
PRESENTACIÓN
Optimizing HF discharge care and follow-up
Ver contenido
Infection and Vaccines
LO MÁS NUEVO

Infección y vacunas

What did the study tell us about the safety of medicines in heart failure?
PRESENTACIÓN
What did the study tell us about the safety of medicines in heart failure?
Ver contenido
Hiding in plain sight – how to detect heart failure in primary care
PRESENTACIÓN
Hiding in plain sight – how to detect heart failure in primary care
Ver contenido
Optimizing HF discharge care and follow-up
PRESENTACIÓN
Optimizing HF discharge care and follow-up
Ver contenido
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
PRESENTACIÓN
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
Ver contenido
Metabolic
LO MÁS NUEVO

Metabólico

Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
PRESENTACIÓN
Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
Ver contenido
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
PRESENTACIÓN
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
Ver contenido
Clinical recommendations for the management of type 2 diabetes
PRESENTACIÓN
Clinical recommendations for the management of type 2 diabetes
Ver contenido
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
PRESENTACIÓN
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
Ver contenido
Oncology
LO MÁS NUEVO

Oncología

The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
PRESENTACIÓN
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
Ver contenido
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
PRESENTACIÓN
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
Ver contenido
Renal protection with SGLT2 inhibitors: what every cardiologist should know
PRESENTACIÓN
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Ver contenido
Medicines in chronic kidney disease
PRESENTACIÓN
Medicines in chronic kidney disease
Ver contenido
Renal
LO MÁS NUEVO

Renal

Chronic kidney disease management
PRESENTACIÓN
Chronic kidney disease management
Ver contenido
Renal protection with SGLT2 inhibitors: what every cardiologist should know
PRESENTACIÓN
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Ver contenido
Kidney outcomes associated with inhibition of SGLT2
PRESENTACIÓN
Kidney outcomes associated with inhibition of SGLT2
Ver contenido
Medicines in chronic kidney disease
PRESENTACIÓN
Medicines in chronic kidney disease
Ver contenido
Respiratory and Immunology
LO MÁS NUEVO

Respiratoria e inmunología

What did the study tell us about the safety of medicines in heart failure?
PRESENTACIÓN
What did the study tell us about the safety of medicines in heart failure?
Ver contenido
Hiding in plain sight – how to detect heart failure in primary care
PRESENTACIÓN
Hiding in plain sight – how to detect heart failure in primary care
Ver contenido
Clinical recommendations for the management of type 2 diabetes
PRESENTACIÓN
Clinical recommendations for the management of type 2 diabetes
Ver contenido
Kidney outcomes associated with inhibition of SGLT2
PRESENTACIÓN
Kidney outcomes associated with inhibition of SGLT2
Ver contenido
Rare Disease
LO MÁS NUEVO

Enfermedad rara

Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
PRESENTACIÓN
Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
Ver contenido
Clinical recommendations for the management of type 2 diabetes
PRESENTACIÓN
Clinical recommendations for the management of type 2 diabetes
Ver contenido
Kidney outcomes associated with inhibition of SGLT2
PRESENTACIÓN
Kidney outcomes associated with inhibition of SGLT2
Ver contenido
Medicines in chronic kidney disease
PRESENTACIÓN
Medicines in chronic kidney disease
Ver contenido
Destacado
LO MÁS NUEVO

Tendencia

The story of heart failure prevention with SGLT2 inhibitors in diabetes: Key learnings for cardiologist
PRESENTACIÓN
The story of heart failure prevention with SGLT2 inhibitors in diabetes: Key learnings for cardiologist
Ver contenido
Cardiologist Practical Guide to Prescribing
INFOGRAFÍA
Cardiologist Practical Guide to Prescribing
Ver contenido
Safety and tolerability of SGLT2 inhibitors – how and when should I initiate treatment
VIDEO
Safety and tolerability of SGLT2 inhibitors – how and when should I initiate treatment
Ver contenido
Cardiorenal benefits of SGLT2 inhibitors
PRESENTACIÓN
Cardiorenal benefits of SGLT2 inhibitors
Ver contenido
Diagnosis and co-morbidities of chronic kidney disease
VIDEO
Diagnosis and co-morbidities of chronic kidney disease
Ver contenido